As part of Biotechmed-2017, National Immunobiological Company signed an agreement on the transfer of technologies for production of a number of immunobiological drugs. The company expects to start production of Russian vaccines for prevention of rotavirus infection, human papilloma virus, chickenpox, etc.
As was told by Sergey Chemezov, the Rostec's head, at the Biotechmed conference, an exclusive agreement on the transfer of technologies for production of vaccines was signed between Farm Aid Ltd. (established by National Immunobiological Company in cooperation with Ishvan Pharmaceuticals, UAE) and two largest global biotechnology companies, Serum Institute of India and Zydus Cadila (Healthcare).
"According to the agreement, Serum Institute of India will transfer to Farm Aid Ltd. the technologies for production of preventive vaccines against rotavirus infection. In the future, technologies for production of a number of other vaccines against diseases relevant to Russia might also be transferred. The transfer will be carried out in several stages, from development of a formulated product and antigens for production of vaccines to the entire process cycle, starting from the antigen production, in the next five years", told Sergey Chemezov.
As was noted before, National Immunobiological Company signed an agreement with Mylan Laboratories Limited, India, at Biotechmed-2017. This will ensure the supply of substances, transfer of technologies and production of modern combined drugs for HIV treatment.